Based on the Direxion Daily Healthcare Bull 3X Shares stock forecast from 0 analysts, the average analyst target price for Direxion Daily Healthcare Bull 3X Shares is not available over the next 12 months. Direxion Daily Healthcare Bull 3X Shares’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Direxion Daily Healthcare Bull 3X Shares is Bullish , which is based on 6 positive signals and 1 negative signals. At the last closing, Direxion Daily Healthcare Bull 3X Shares’s stock price was USD 107.63. Direxion Daily Healthcare Bull 3X Shares’s stock price has changed by +4.91% over the past week, -10.40% over the past month and -0.19% over the last year.
No recent analyst target price found for Direxion Daily Healthcare Bull 3X Shares
No recent average analyst rating found for Direxion Daily Healthcare Bull 3X Shares
Company Overview Direxion Daily Healthcare Bull 3X Shares
The fund invests at least 80% of its net assets in financial instruments, that, in combination, provide 3X daily leveraged exposure to the index, consistent with the fund's investment objective. The index includes domestic companies from the healthcare sector, which includes: pharmaceuticals; health care equipment and supplies; health care providers and services; biotechnology; life sciences tools and services; and etc. It is non-diversified. Read Less
The fund invests at least 80% of its net assets in financial instruments, that, in combination, provide 3X daily leveraged exposure to the index, consistent with the fund's investment objective. The index includes domestic companies from the healthcare sector, which includes: pha...Read More
Stock Target Advisor's fundamental analysis for Direxion Daily Healthcare Bull 3X Shares's stock is Bullish .
CURE stock's dividend yield is 1.53%.
Our analysis grades CURE stock's dividend yield at D-. This means that CURE stock's dividend yield is above 60% of the stocks in the Trading--Leveraged Equity sector in the NYE exchange.
Based on this CURE may be a average dividend stock for its sector.
Unfortunately we do not have enough data on CURE's stock to indicate what its average analyst target is.
CURE stock's Price/Earning ratio is 0.75.
Our analysis grades CURE stock's Price / Earning ratio at A+. This means that CURE stock's Price/Earning ratio is above 0% of the stocks in the Trading--Leveraged Equity sector in the NYE exchange.
Based on this CURE may be undervalued for its sector.
The last closing price of CURE's stock was USD 107.63.
The most recent market capitalization for CURE is USD 0.21B.
Unfortunately we do not have enough analyst data on CURE's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Direxion Daily Healthcare Bull 3X Shares's stock.
As per our most recent records Direxion Daily Healthcare Bull 3X Shares has 0 Employees.
Sorry we do not have any infomation available on Direxion Daily Healthcare Bull 3X Shares's address.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
Underpriced compared to book value
The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Underpriced compared to earnings
The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Below median total returns
The company has under performed its peers on annual average total returns in the past 5 years.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for CURE !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
Stocktwits
